share_log

ITeos Therapeutics (NASDAQ:ITOS) Stock Price Down 3.5%

ITeos Therapeutics (NASDAQ:ITOS) Stock Price Down 3.5%

ITEO 股價下跌 3.5%
Financial News Live ·  2023/01/23 15:01

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating)'s share price fell 3.5% during trading on Monday . The company traded as low as $20.93 and last traded at $20.93. 36,725 shares changed hands during trading, a decline of 89% from the average session volume of 346,680 shares. The stock had previously closed at $21.70.

ITEOS 治療學公司（納斯達克：ITOS-獲取評級）的股價在星期一交易期間下跌了 3.5％。該公司的交易價格低至 20.93 美元，最後交易價格為 20.93 美元。36,725 股股份在交易過程中變手，較 346,680 股平均交易量下跌 89%。該股票之前已收盤 21.70 美元。

iTeos Therapeutics Trading Down 3.0 %

ITEOS 治療學交易下降 3.0%

The stock's 50 day moving average price is $19.76 and its 200 day moving average price is $21.06. The company has a market capitalization of $748.85 million, a price-to-earnings ratio of 3.15 and a beta of 1.38.

該股票的 50 日移動平均價格為 19.76 美元，其 200 日移動平均價格為 21.06 美元。該公司的市值為 74,885 萬美元，3.15 的價格與收益比率和 1.38 的測試版。

Get
取得
iTeos Therapeutics
ITEOS 治療學
alerts:
警報：

iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. The business had revenue of $19.49 million for the quarter, compared to analyst estimates of $42.05 million. On average, research analysts expect that iTeos Therapeutics, Inc. will post 2.85 earnings per share for the current year.

ITEOS 治療學（NASDAQ：ITOS-獲取評級）上次發布了其收益結果，週四，11 月 10 日。該公司報告了本季度每股盈利 0.03 美元，缺失分析師的共識估計為 0.07 美元（0.04 美元）。ITEOS 治療的股本回報率為 42.62％，淨利潤率為 57.48%。該業務本季度的收入為 19.49 萬美元，而分析師估計為 4.05 億美元。平均而言，研究分析師預計，iToS 治療股份有限公司將在本年度發布每股 2.85 收益。

Institutional Trading of iTeos Therapeutics

ITEOS 治療學的機構交易

Several large investors have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in shares of iTeos Therapeutics by 16.0% during the 3rd quarter. BlackRock Inc. now owns 4,317,157 shares of the company's stock worth $82,241,000 after purchasing an additional 595,920 shares in the last quarter. State Street Corp lifted its position in shares of iTeos Therapeutics by 44.8% during the 2nd quarter. State Street Corp now owns 2,478,332 shares of the company's stock worth $51,054,000 after buying an additional 766,441 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of iTeos Therapeutics by 7.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,751,100 shares of the company's stock worth $33,358,000 after buying an additional 121,514 shares during the last quarter. Candriam S.C.A. lifted its position in shares of iTeos Therapeutics by 15.2% during the 2nd quarter. Candriam S.C.A. now owns 787,651 shares of the company's stock worth $16,225,000 after buying an additional 103,839 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of iTeos Therapeutics by 146.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company's stock worth $11,522,000 after buying an additional 332,625 shares during the last quarter.
一些大型投資者最近修改了股票的持有量。在第三季度，貝萊德公司在 ITEOS 治療的股份增長了 16.0%。在上一季度額外購買 595,920 股股份後，貝萊德公司現在擁有該公司股票 4,317,157 股價值 82,241,000 美元。州街公司在第二季度通過 44.8% 提升了其在 ITEOS 治療的股份中的地位.州街公司現在擁有該公司股票 2,478,332 股股份，價值 51,054,000 美元，在上一季度額外購買了 766,441 股股票。領航集團股份有限公司在第三季度將其在 ITEOS 治療學的股份中的地位提升了 7.5％。領航集團股份有限公司在上一季度額外購買 121,514 股股份後，擁有該公司股票價值 33,358,000 美元的 1,751,100 股股份。坎德里亞姆 S.C.A. 在第二季度提升了其在 ITEOS 治療的股份地位 15.2%.在上一季度額外購買 103,839 股股份後，坎迪瑞姆股份有限公司現在擁有該公司股票的 787,651 股價值 16,225,000 美元。最後，摩根大通公司在第二季度將其在 ITEO 治療學股份的地位提升了 146.7%。摩根大通公司在上一季度額外購買 332,625 股股份後，現擁有該公司股票價值 11,522,000 美元的 559,299 股股份。

About iTeos Therapeutics

關於 ITEOS 治療

(Get Rating)

(取得評分)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Itemos Therapetics, Inc 是一家臨床階段生物製藥公司，致力於為患者提供免疫腫瘤治療的發現和開發。公司的產品線包括二期臨床試驗中腺苷 A2AR 拮抗劑的小分子拮抗劑，以及 EOS-448（一種 TIGIT 或 T 細胞免疫受體的拮抗劑），具有 Ig 和 ITIM 域的拮抗劑（在 1/2 期臨床試驗中），以及用於接合 Fc γ 受體或 Fc。R 激活樹突狀細胞和巨噬細胞，促進抗體依賴性細胞毒性或 ADCC 活性。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
  • Can We Trust The Rally In The S&P 500
  • Energy Surge: Four Oil-And-Gas Stocks Setting Up In Bullish Bases
  • One ETF Trading Strategy to Beat the Market in 2023
  • Is Wayfair Still Way Cheap For Investors?
  • When Does Pfizer Become A Bargain?
  • 獲取有關 ITEOS 治療學研究報告的免費副本
  • 我們可以相信標普 500 的反彈
  • 能源激增：四股石油和天然氣股票在看漲基礎中建立
  • 一種在 2023 年擊敗市場的 ETF 交易策略
  • 威費爾對於投資者來說仍然便宜嗎？
  • 輝瑞什麼時候成為一個討價還價？

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收有關 ITEOS 治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 ITEOS 治療和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論